PetMed Express, Inc. (NASDAQ:PETS – Get Free Report) major shareholder Silvercape Investments Ltd purchased 118,200 shares of the business’s stock in a transaction dated Friday, August 1st. The shares were acquired at an average price of $3.21 per share, with a total value of $379,422.00. Following the completion of the acquisition, the insider owned 2,478,696 shares of the company’s stock, valued at approximately $7,956,614.16. The trade was a 5.01% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Major shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.
Silvercape Investments Ltd also recently made the following trade(s):
- On Friday, July 18th, Silvercape Investments Ltd purchased 17,565 shares of PetMed Express stock. The shares were acquired at an average price of $3.23 per share, with a total value of $56,734.95.
- On Thursday, July 17th, Silvercape Investments Ltd purchased 31,701 shares of PetMed Express stock. The shares were acquired at an average price of $3.15 per share, with a total value of $99,858.15.
- On Wednesday, July 2nd, Silvercape Investments Ltd purchased 2,817 shares of PetMed Express stock. The shares were acquired at an average price of $3.22 per share, with a total value of $9,070.74.
- On Tuesday, May 20th, Silvercape Investments Ltd purchased 7,401 shares of PetMed Express stock. The shares were acquired at an average price of $3.95 per share, with a total value of $29,233.95.
PetMed Express Trading Down 1.2%
Shares of NASDAQ PETS opened at $3.20 on Tuesday. The business has a fifty day simple moving average of $3.50 and a 200 day simple moving average of $3.84. The firm has a market capitalization of $66.11 million, a price-to-earnings ratio of 320.32 and a beta of 0.82. PetMed Express, Inc. has a one year low of $2.90 and a one year high of $6.85.
Institutional Inflows and Outflows
Analysts Set New Price Targets
A number of brokerages have recently commented on PETS. Morgan Stanley cut their price target on PetMed Express from $3.50 to $3.20 and set an “underweight” rating for the company in a report on Thursday, April 17th. Wall Street Zen lowered PetMed Express from a “hold” rating to a “sell” rating in a report on Sunday.
Get Our Latest Analysis on PETS
PetMed Express Company Profile
PetMed Express, Inc, together with its subsidiaries, operates as a pet pharmacy in the United States. The company markets prescription and non-prescription pet medications, health products, and other supplies for dogs, cats, and horses. It offers non-prescription medications and supplies, such as flea and tick control products, bone and joint care products, vitamins, treats, nutritional supplements, hygiene products, and household pet supplies; and prescription medications, including heartworm preventatives, flea and tick preventatives, arthritis, dermatitis, thyroid, diabetes, pain medications, heart/blood pressure, and other specialty medications, as well as generic substitutes.
Featured Articles
- Five stocks we like better than PetMed Express
- How to Invest in Small Cap Stocks
- Analysts Make a Quantum Bet on D-Wave’s Cryogenic Packaging
- Stock Dividend Cuts Happen Are You Ready?
- Traders Turn Bullish on Housing Stocks Again—3 Leading the Way
- 3 Tickers Leading a Meme Stock Revival
- Onsemi’s August Pullback Is a Signal to Buy for Tech Investors
Receive News & Ratings for PetMed Express Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PetMed Express and related companies with MarketBeat.com's FREE daily email newsletter.